Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ: EDIT )

1.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,596
Open 1.250
Bid (Size) 1.260 (2)
Ask (Size) 1.290 (100)
Prev. Close 1.250
Today's Range 1.250 - 1.250
52wk Range 1.120 - 11.58
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire

Performance

YTD
-4.58%
-4.58%
1 Month
-0.79%
-0.79%
3 Month
-62.12%
-62.12%
6 Month
-68.11%
-68.11%
1 Year
-84.62%
-84.62%

More News

Read More
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
Via Benzinga
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
12 Analysts Have This To Say About Editas Medicine
Via Benzinga
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
Via Benzinga
Where Editas Medicine Stands With Analysts
Via Benzinga
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Via Benzinga
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
Via Talk Markets
Topics Stocks / Equities
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Via Benzinga
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
From Editas Medicine, Inc.
Via GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
Looking for Stock Bargains With Room to Run? Try This.
Via The Motley Fool
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.